Initial experience with the intravascular contrast agent NC100150-injection (Clariscan) for breath-hold and navigator-gated magnetic resonance coronary artery imaging.
OBJECTIVE
To examine magnetic resonance coronary artery imaging after NC100150-Injection.


METHODS
Breath-hold and navigator-gated images were acquired in five patients.


RESULTS
Breath-hold image quality, coronary artery-fat SDNR, and coronary artery SNR improved. Respiratory artifacts due to reduced liver signal intensity degraded navigator-gated image quality.


CONCLUSIONS
NC100150-Injection improves breath-hold coronary artery imaging. Navigator-gated acquisitions should use techniques that are insensitive to T2* effects.
Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, United Kingdom.
Nicholas H
NH
Bunce
Jennifer
J
Keegan
Peter D
PD
Gatehouse
James C C
JC
Moon
David N
DN
Firmin
Volker
V
Hoffmann
Dudley J
DJ
Pennell
D000368:Aged; D003287:Contrast Media; D003331:Coronary Vessels / Q000473:pathology*; D003911:Dextrans; D052203:Ferrosoferric Oxide; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007501:Iron; D018810:Magnetic Resonance Angiography / Q000379:methods*; D058185:Magnetite Nanoparticles; D008875:Middle Aged; D010087:Oxides; D018709:Statistics, Nonparametric
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide